---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091353"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:29:30.042944+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports Q3 net loss $20.7M; reiterates Aug 29 PDUFA for ONS-5010

## Summary
- Net loss attributable to common stockholders of $20.7M ($0.08/share) vs $17.5M in prior-year quarter.
- Cash and cash equivalents of $33.7M expected to fund operations through potential BLA approval in Q3 2023.
- FDA PDUFA goal date of August 29, 2023 for ONS-5010 (ophthalmic bevacizumab) for wet AMD.
- Pre-launch activities ongoing with AmerisourceBergen distribution partnership for U.S. launch.
- MAA decision from EMA CHMP for ONS-5010 in EU expected in first half of 2024.

## SEC filing metadata
- accession: 0001104659-23-091353
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/0001104659-23-091353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/tm2323752d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091353
- JSON: https://secwatch.observer/filing/0001104659-23-091353.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091353.txt

## Key facts
- Earnings Releases
  Outlook Therapeutics, Inc. reported financial results for third fiscal quarter ended June 30, 2023.
  - Period: third fiscal quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, Outlook Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for its third fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/0001104659-23-091353-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.